ARCHIVES

New benchmark for CCSG award funding will be lowered from 20 percent of NCI research base to 15 percent, the program’s “reality ratio,” Karen Antman tells NCAB.

This article is from The Cancer Letter archive.

Vol. 30 No. 38 | October 8, 2004

Download PDF Visit The Full Archive

Related Articles

Yervoy-Nivolumab Combination Treatment Shrinks Tumors 80 Percent in Three Months

May 31, 2013

Adherez Issued U.S. Patent for Catenin Molecule Inhibition.

July 4, 2003

FDA Grants Six-Month Priority Review To Nolvadex For DCIS Adjuvant Treatment.

March 31, 2000

NY Attorney General Sues Drug Companies Over Cancer Drug Pricing Deals

February 14, 2003

In Brief: Gene Therapy Pioneer Michael Blaese To Leave NIH For Biotechnology Firm

January 23, 1998

Institute of Medicine Elects 80 New Members

October 24, 2014